

**ASHP Abstracts & Program Resources on CDROM
2006 Midyear Clinical Meeting
December 3-7, 2006 Anaheim, CA**

**Session: Pharmacogenomics 101: From Research to Clinical Practice
Program #204-000-06-257-L04**

Moderator: Carol J. Hope, Pharm.D., M.S., Information Systems Pharmacist, The Johns Hopkins Hospital, Baltimore, MD

Speaker Contact Information

Amber L. Beitelshes, PharmD, MPH
Research Assistant Professor of Medicine
Washington University
660 South Euclid Ave, Box 8086
St. Louis, MO 63112 USA
abeitels@im.wustl.edu

Presentation:

Integration of Genomics into Therapy Selection

Amber L. Beitelshes, Pharm.D., M.P.H., Research Assistant Professor of Medicine, Center for Cardiovascular Research, Washington University School of Medicine, St. Louis, MO (PI-166)

Biography

Amber L. Beitelshes, PharmD, MPH

After earning her Pharm.D. from the University of Florida, Amber completed a Pharmacy Practice Residency at the University of Illinois at Chicago. She then returned to the University of Florida to complete a 3-year postdoctoral fellowship in Cardiovascular Pharmacogenomics under the mentorship of Dr. Julie Johnson. In August of 2005, Amber joined the faculty of Washington University School of Medicine as Research Assistant Professor in the Cardiovascular Division. Her research is aimed at understanding how variability in genes related to cardiac metabolism impact response to commonly used cardiovascular medications, such as ACE inhibitors, angiotensin receptor blockers, and β -blockers.

Presentation Outline

- Integration of genomics into clinical practice
- I. Overview of pharmacogenomics
- II. Primer/Terminology
- III. Warfarin example
- IV. Bucindolol example
- V. Future considerations

Abstract

Integration Of Genomics Into Clinical Practice

Amber L. Beitelshes, PharmD, MPH
Washington University, Cardiovascular Division, 660 South Euclid Ave., Box 8086, St. Louis, MO 63112, USA. E-mail: abeitels@im.wustl.edu

Sequencing of the human genome affords a new tool for understanding genetic determinants of drug response. This information, if used to its fullest potential, can lead health care professionals to make wiser medications choices; and thus, provide more rational therapeutics. Pharmacogenetics-enhanced therapy might facilitate providing the right drugs to the right patients, rather than prescribing through the currently empirical trial and error approach. Pharmacogenomics could be important for conserving valuable healthcare resources and

**ASHP Abstracts & Program Resources on CDROM
2006 Midyear Clinical Meeting
December 3-7, 2006 Anaheim, CA**

reducing the heterogeneity of drug efficacy and toxicity. Health care professionals must have an understanding of the tools used to generate genomic data, and more importantly be able to translate pharmacogenetic information into clinical practice through interpretation of scientific literature, interpretation of test results, and counseling patients regarding genomic medicine. This information will likely be available for making therapeutic decisions in the not so distant future for agents such as warfarin or bucindolol.

Learning Objectives:

1. Describe the process of DNA mapping.
2. Write the definitions of gene, SNPs, RFLP, and linkage map.
3. List at least 3 effects pharmacogenomics may have on pharmacy practice.

Self-Assessment Questions: True or False:

1. A polymorphism is variation in the genetic code that occurs in at least 1% of the population.
2. Patients genotyped for CYP2C9 and VKORC1 to determine their warfarin starting dose will not require therapeutic monitoring of their INR.
3. Pharmacists are important to successfully incorporating genomics into pharmacotherapy selection because of their unique clinical, molecular, and pharmacological knowledge base.

Answers

1 (T), 2 (F), 3 (T)

Bibliography

1. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. *N Engl J Med*. 2005;352:2285-93.
2. Evans WE, McLeod HL. Pharmacogenomics — drug disposition, drug targets, and side effects. *N Engl J Med*. 2003;348:538-49.
3. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, et al. A polymorphism within a conserved β 1-adrenergic receptor motif alters cardiac function and β -blocker response in human heart failure. *PNAS* 2006;103:11288-11293.
4. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. *Ann Rev Genom Hum Genet* 2001;2:9-39.
5. Guttmacher AW, Collins FS. Genomic medicine — a primer. *New Engl J Med* 2002 347:1512-20.
6. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, et al. *Thromb Haemost* 2004;91:87-94.
7. Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. *Tromb Haemost* 2005;93:700-5.
8. Higashi MK, Veenstra DL, Kondo M, Wittowsky AK, Srinouanprachanh SL, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. *JAMA* 2002;287:1690-1698.

Slides: none provided